Women's Health Therapeutics Market Size, Share & Trends Analysis Report By Type (Infection, Pregnancy, Oncology), By Region (North America, Europe, APAC, LATAM, MEA), And Segment Forecasts, 2018 - 2025

Published: Jul, 2018 | Pages: 140 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global women's health therapeutics market size is expected to reach USD 210.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the forecast period. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.

The women's health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.

In January 2018, Melinta Therapeutics, Inc. acquired The Medicines Company's infectious diseases business. This acquisition would help to the former expand its portfolio by offering life-saving treatment options. In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer. Increasing investments by top market players are anticipated to propel the global market over the forecast period.

There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.

Further key findings from the report suggest:

• By type, infection accounted for the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to rising drug approvals, availability of diagnostic tests and treatments, and high incidence of infectious diseases

• Ovarian cancer is anticipated to be the fastest-growing sub-segment of oncology during the forecast period due to high prevalence of ovarian cancer and approval of new and improved drugs

• North America is expected to maintain its dominance in the coming years due to high awareness about women's health, increase in number of advanced diagnostic and treatment methods, mergers and acquisitions by market players, and rise in infections and cancer cases

• Asia Pacific is likely to witness significant growth over the next decade due to improving healthcare facilities, increase in commercialization and approval of products, and investment by market players

• Some of the key players in women's health therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd, AstraZeneca, Bristol-Myers Squibb (BMS) Company, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Sanofi.

 Table of Contents

Chapter 1 Research Methodology
                 1.1 Information Procurement
                 1.2 Data Analysis

Chapter 2 Executive Summary
                 2.1 Market Snapshot

Chapter 3 Market Variables, Trends & Scope
                 3.1 Market Segmentation and Scope
                     3.1.1 Market driver analysis
                         3.1.1.1 Rising incidence of chronic and lifestyle-associated disorders among women
                         3.1.1.2 Increasing investments
                         3.1.1.3 Growing awareness and introduction of new drug therapies
                         3.1.1.4 High prevalence of infectious diseases among women
                     3.1.2 Market restraint analysis
                         3.1.2.1 High cost of therapies
                 3.2 Penetration & Growth Prospects Mapping
                 3.3 Women's Health Therapeutics Market - PESTLE Analysis
                 3.4 Industry Analysis - Porter's
                 3.5 Women's Health Therapeutics Market: List of Manufacturers at Regional Level
                 3.6 Clinical Pipeline Analysis
                 3.7 Regulatory Scenario
                     3.7.1 U.S. regulatory scenario
                     3.7.2 Canada regulatory scenario
                     3.7.3 EU member states regulatory scenario
                     3.7.4 Japan regulatory scenario
                     3.7.5 China regulatory scenario
                     3.7.6 India regulatory scenario
                     3.7.7 Brazil regulatory scenario
                     3.7.8 Mexico regulatory scenario
                     3.7.9 South Africa regulatory scenario

Chapter 4 Women's Health Therapeutics Market: Type Estimates & Trend Analysis
                 4.1 Women's Health Therapeutics Market: Type Analysis
                 4.2 Infection
                     4.2.1 Infection market, 2014 - 2025 (USD Million)
                 4.3 Pregnancy
                     4.3.1 Pregnancy market, 2014 - 2025 (USD Million)
                 4.4 Oncology
                     4.4.1 Oncology market, 2014 - 2025 (USD Million)
                     4.4.2 Cervical cancer
                         4.4.2.1 Cervical cancer market, 2014 - 2025 (USD Million)
                     4.4.3 Uterine Cancer
                         4.4.3.1 Uterine cancer market, 2014 - 2025 (USD Million)
                     4.4.4 Ovarian cancer
                         4.4.4.1 Ovarian cancer market, 2014 - 2025 (USD Million)
                     4.4.5 Vaginal and vulvar cancer
                         4.4.5.1 Vaginal & vulvar cancer market, 2014 - 2025 (USD Million)

Chapter 5 Women's Health Therapeutics Market: Regional Estimates & Trend Analysis
                 5.1 Women's Health Therapeutics Market Share, By Region, 2014 & 2025
                 5.2 North America
                     5.2.1 North America women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.2.2 U.S.
                         5.2.2.1 U.S. women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.2.3 Canada
                         5.2.3.1 Canada women's health therapeutics market, 2014 - 2025 (USD million)
                 5.3 Europe
                     5.3.1 U.K.
                         5.3.1.1 U.K. women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.3.2 Germany
                         5.3.2.1 Germany women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.3.3 France
                         5.3.3.1 France women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.3.4 Italy
                         5.3.4.1 Italy women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.3.5 Spain
                         5.3.5.1 Spain women's health therapeutics market, 2014 - 2025 (USD Million)
                 5.4 Asia Pacific
                     5.4.1 Asia Pacific women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.4.2 Japan
                         5.4.2.1 Japan women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.4.3 China
                         5.4.3.1 China women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.4.4 India
                         5.4.4.1 India women's health therapeutics market, 2014 - 2025 (USD Million)
                 5.5 Latin America
                     5.5.1 Latin America women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.5.2 Brazil
                         5.5.2.1 Brazil women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.5.3 Mexico
                         5.5.3.1 Mexico women's health therapeutics market, 2014 - 2025 (USD Million)
                 5.6 Middle East and Africa (MEA)
                     5.6.1 MEA women's health therapeutics market, 2014 - 2025 (USD Million)
                     5.6.2 South Africa
                         5.6.2.1 South Africa women's health therapeutics market, 2014 - 2025 (USD Million)

Chapter 6 Competitive Landscape
                 6.1 Strategy Framework
                 6.2 Women's Health Therapeutics Competitive Landscape: Market Position Analysis (Based on Revenue, Product Portfolio, Regional Presence, and Recent Updates)
                 6.3 Company Profiles
                     6.3.1 Bayer AG
                         6.3.1.1 Company Overview
                         6.3.1.2 Financial Performance
                         6.3.1.3 Product Benchmarking
                         6.3.1.4 Strategic Initiatives
                     6.3.2 Merck & Co., Inc.
                         6.3.2.1 Company Overview
                         6.3.2.2 Financial Performance
                         6.3.2.3 Product Benchmarking
                         6.3.2.4 Strategic Initiatives
                     6.3.3 Pfizer, Inc.
                         6.3.3.1 Company Overview
                         6.3.3.2 Financial Performance
                         6.3.3.3 Product Benchmarking
                         6.3.3.4 Strategic Initiatives
                     6.3.4 Teva Pharmaceutical Industries Ltd.
                         6.3.4.1 Company Overview
                         6.3.4.2 Financial Performance
                         6.3.4.3 Product Benchmarking
                         6.3.4.4 Strategic Initiatives
                     6.3.5 AstraZeneca
                         6.3.5.1 Company Overview
                         6.3.5.2 Financial Performance
                         6.3.5.3 Product Pipeline
                         6.3.5.4 Product Benchmarking
                         6.3.5.5 Strategic Initiatives
                     6.3.6 Bristol-Myers Squibb Company
                         6.3.6.1 Company Overview
                         6.3.6.2 Financial Performance
                         6.3.6.3 Product Benchmarking
                         6.3.6.4 Strategic Initiatives
                     6.3.7 Eli Lilly and Company
                         6.3.7.1 Company Overview
                         6.3.7.2 Financial Performance
                         6.3.7.3 Product Benchmarking
                         6.3.7.4 Strategic Initiatives
                     6.3.8 Novartis AG
                         6.3.8.1 Company Overview
                         6.3.8.2 Financial Performance
                         6.3.8.3 Product Benchmarking
                         6.3.8.4 Strategic Initiatives
                     6.3.9 GlaxoSmithKline plc
                         6.3.9.1 Company Overview
                         6.3.9.2 Financial Performance
                         6.3.9.3 Product Benchmarking
                         6.3.9.4 Strategic Initiatives
                     6.3.10 F. Hoffmann-La Roche Ltd
                         6.3.10.1 Company Overview
                         6.3.10.2 Financial Performance
                         6.3.10.3 Product Benchmarking
                         6.3.10.4 Strategic Initiatives
                     6.3.11 Mylan N.V.
                         6.3.11.1 Company Overview
                         6.3.11.2 Financial Performance
                         6.3.11.3 Product Benchmarking
                         6.3.11.4 Strategic Initiatives
                     6.3.12 Sun Pharmaceutical Industries Ltd.
                         6.3.12.1 Company Overview
                         6.3.12.2 Financial Performance
                         6.3.12.3 Product Benchmarking
                         6.3.12.4 Strategic Initiatives
                     6.3.13 Sanofi
                         6.3.13.1 Company Overview
                         6.3.13.2 Financial Performance
                         6.3.13.3 Product Benchmarking
                         6.3.13.4 Strategic Initiatives
                     6.3.14 CooperSurgical, Inc.
                         6.3.14.1 Company Overview
                         6.3.14.2 Product Benchmarking
                         6.3.14.3 Strategic Initiatives

List of Tables

TABLE 1 Market of Major Drugs
TABLE 2 Medicaid spending among beneficiaries with cervical cancer in Texas, 2014
TABLE 3 North America women's health therapeutics market, by country, 2014 - 2025 (USD Million)
TABLE 4 North America women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 5 North America oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 6 U.S. women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 7 U.S. oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 8 Canada women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 9 Canada oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 10 Europe women's health therapeutics market, by country, 2014 - 2025 (USD Million)
TABLE 11 Europe women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 12 Europe oncology women's health therapeutics, by type, 2014 - 2025 (USD Million)
TABLE 13 U.K. women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 14 U.K. oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 15 Germany women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 16 Germany oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 17 France women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 18 France oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 19 Italy women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 20 Italy oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 21 Spain women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 22 Spain oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 23 Asia Pacific women's health therapeutics market, by country, 2014 - 2025 (USD Million)
TABLE 24 Asia Pacific women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 25 Asia Pacific oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 26 Japan women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 27 Japan oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 28 China women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 29 China oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 30 India women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 31 India oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 32 Latin America women's health therapeutics market, by country, 2014 - 2025 (USD Million)
TABLE 33 Latin America women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 34 Latin America oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 35 Brazil women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 36 Brazil oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 37 Mexico women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 38 Mexico oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 39 Middle East & Africa women's health therapeutics market, by country, 2014 - 2025 (USD Million)
TABLE 40 Middle East & Africa women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 41 Middle East & Africa oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 42 South Africa women's health therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 43 South Africa oncology women's health therapeutics market, by type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary 2017, (USD million)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Increasing prevalence of chronic diseases, 1995 - 2030 (million)
FIG. 12 Market restraint relevance analysis (Current & future impact)
FIG. 13 Average monthly HIV drug expenditure in the U.S.
FIG. 14 Penetration & growth prospect mapping
FIG. 15 Women's health therapeutics market - PESTLE analysis
FIG. 16 Porter's five forces analysis
FIG. 17 List of manufacturers at regional level
FIG. 18 Clinical pipeline analysis
FIG. 19 Drug development process in Canada
FIG. 20 Women's health therapeutics market, type outlook: Key takeaways
FIG. 21 Women's health therapeutics market: Type movement analysis
FIG. 22 All reportable infectious disease incidence rates, Durham and Ontario, 2010-2015
FIG. 23 Infection market, 2014 - 2025 (USD Million)
FIG. 24 Pregnancy market, 2014 - 2025 (USD Million)
FIG. 25 Oncology market, 2014 - 2025 (USD Million)
FIG. 26 Cervical cancer market, 2014 - 2025 (USD Million)
FIG. 27 Uterine cancer market, 2014 - 2025 (USD Million)
FIG. 28 Ovarian cancer market, 2014 - 2025 (USD Million)
FIG. 29 Vaginal & vulvar cancer market, 2014 - 2025 (USD Million)
FIG. 30 Regional market place: Key takeaways
FIG. 31 Women's health therapeutics market: Regional outlook, 2017 & 2025
FIG. 32 North America women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 U.S. women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 Canada women's health therapeutics market, 2014 - 2025 (USD million)
FIG. 35 Europe women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 U.K. women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 Germany women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 38 France women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 39 Italy women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 40 Spain women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 41 Asia Pacific women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 42 Japan women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 43 China women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 44 India women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 45 Latin America women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 46 Brazil women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 47 Mexico women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 48 Middle East & Africa women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 49 South Africa women's health therapeutics market, 2014 - 2025 (USD Million)
FIG. 50 Strategy framework
FIG. 51 Women's health therapeutics competitive landscape: Market position analysis (based on overall revenue, products, regional presence, strategic initiatives)